Skip to main content

Advertisement

SpringerLink
Log in

Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy

  • Skin Cancer (T Ito, Section Editor
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

While most patients with early-stage mycosis fungoides (MF) follow an indolent course, patients with advanced-stage MF/Sézary syndrome (SS) have a poor prognosis with a median survival of less than 5 years. Although there are a number of treatments currently available, achieving and maintaining a durable response remain challenging, especially in advanced-stage MF/SS. The choice of frontline therapy is dependent on the stage of disease. For early-stage MF, the treatment concept is to control skin lesions mainly by skin-directed therapies, such as topical therapies, phototherapies, and radiotherapies. For advanced-stage MF/SS, systemic treatments by biological or targeted therapies including bexarotene and interferon either alone or in combination are tried first, with more immunosuppressive chemotherapies being reserved for refractory or rapidly progressive disease. Recent improvements in biological or targeted therapies include brentuximab vedotin and mogamulizumab. When biopsy samples have 10% or more CD30-positive malignant cells, brentuximab vedotin, an anti-CD30 antibody conjugated to monomethyl auristin E, can be a desirable treatment option. For cases with blood involvement, mogamulizumab, an antibody binding to C-C chemokine receptor 4, is effective with high response rates. In the refractory setting, alemtuzumab, histone deacetylase inhibitors, pralatrexate, gemcitabine, and doxorubicin are considered as the treatment option. Because only allogeneic hematopoietic stem cell transplantation can offer a chance of cure with durable complete remission, advanced-stage patients with a markedly short life expectancy should be evaluated for eligibility. Given that there are few randomized controlled studies in the literature, it is necessary to investigate which therapy is preferable for each patient with MF/SS by comparative prospective trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85. https://doi.org/10.1182/blood-2004-09-3502.

    Article  CAS  PubMed  Google Scholar 

  2. Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496–526. https://doi.org/10.1111/bjd.17240.

    Article  CAS  PubMed  Google Scholar 

  3. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–9. https://doi.org/10.1200/JCO.2009.27.7665.

    Article  PubMed  Google Scholar 

  4. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784–90. https://doi.org/10.1056/NEJM198912283212603.

    Article  CAS  PubMed  Google Scholar 

  5. Hughes CFM, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81. https://doi.org/10.1182/blood-2014-07-588236.

    Article  CAS  PubMed  Google Scholar 

  6. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol. 2014;70(2):205.e1–205.e16. https://doi.org/10.1016/j.jaad.2013.07.049.

    Article  Google Scholar 

  7. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(D):949–54. https://doi.org/10.1001/archderm.134.8.949.

    Article  CAS  PubMed  Google Scholar 

  8. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–73. https://doi.org/10.1001/archderm.139.2.165.

    Article  CAS  PubMed  Google Scholar 

  9. Lindahl LM, Fenger-Grøn M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2014;170(3):699–704. https://doi.org/10.1111/bjd.12620.

    Article  CAS  PubMed  Google Scholar 

  10. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32. https://doi.org/10.1001/2013.jamadermatol.541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22(5):802–10. https://doi.org/10.1016/0190-9622(90)70112-U.

    Article  CAS  PubMed  Google Scholar 

  12. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–32. https://doi.org/10.1001/archderm.138.3.325.

    Article  CAS  PubMed  Google Scholar 

  13. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15. https://doi.org/10.1016/S0190-9622(03)01475-0.

    Article  PubMed  Google Scholar 

  14. •• Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(3):335–41. https://doi.org/10.1001/jamadermatol.2018.5204 A meta-analysis of seven studies including 778 patients with stage IA–IIA MF revealed that CR rate was significantly higher in patients treated with PUVA. CR was found to be 73.8% (389/527) for patients who received PUVA compared with 62.2% (156/251) for those who received NBUVB.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Henseler T, Hönigsmann H, Wolff K, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet. 1981;317(8225):853–7. https://doi.org/10.1016/S0140-6736(81)92137-1.

    Article  Google Scholar 

  16. Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553–62. https://doi.org/10.1016/j.jaad.2011.04.004.

    Article  CAS  PubMed  Google Scholar 

  17. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:22–31. https://doi.org/10.1111/j.1468-3083.2012.04520.x.

    Article  CAS  PubMed  Google Scholar 

  18. Vieyra-Garcia P, Fink-Puches R, Porkert S, Lang R, Pöchlauer S, Ratzinger G, et al. Evaluation of low-dose, low-frequency oral psoralen-UV-A treatment with or without maintenance on early-stage mycosis fungoides: a randomized clinical trial. JAMA Dermatol. 2019;155(5):538–47. https://doi.org/10.1001/jamadermatol.2018.5905.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol. 2005;44(12):1016–21. https://doi.org/10.1111/j.1365-4632.2004.02322.x.

    Article  CAS  PubMed  Google Scholar 

  20. Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008;158(4):659–78. https://doi.org/10.1111/j.1365-2133.2007.08415.x.

    Article  CAS  PubMed  Google Scholar 

  21. Gao C, McCormack C, Van Der Weyden C, Goh MS, Campbell BA, Twigger R, et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome. Blood. 2019;134(16):1346–50. https://doi.org/10.1182/blood.2019000765.

    Article  PubMed  Google Scholar 

  22. Edelson RL. Photopheresis: a new therapeutic concept. Yale J Biol Med. 1989;62(6):565–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med. 1987;316(6):297–303. https://doi.org/10.1056/NEJM198702053160603.

    Article  CAS  PubMed  Google Scholar 

  24. Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054–60. https://doi.org/10.1001/archderm.138.8.1054.

    Article  PubMed  Google Scholar 

  25. Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen IR, Edelson RL, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43(1 1):54–60. https://doi.org/10.1067/mjd.2000.105510.

    Article  CAS  PubMed  Google Scholar 

  26. Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747–53. https://doi.org/10.1016/j.ijrobp.2012.05.034.

    Article  PubMed  Google Scholar 

  27. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8. https://doi.org/10.1016/j.ijrobp.2008.06.1918.

    Article  PubMed  Google Scholar 

  28. Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the european organization for research and treatment of cancer (EORTC) cutaneous lymphoma project group. J Am Acad Dermatol. 2002;47(3):364–70. https://doi.org/10.1067/mjd.2002.123482.

    Article  PubMed  Google Scholar 

  29. Chowdhary M, Chhabra AM, Kharod S, Marwaha G. Total skin electron beam therapy in the treatment of mycosis fungoides: a review of conventional and low-dose regimens. Clin Lymphoma Myeloma Leuk. 2016;16(12):662–71. https://doi.org/10.1016/j.clml.2016.08.019.

    Article  PubMed  Google Scholar 

  30. Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol. 2011;147(5):561–7. https://doi.org/10.1001/archdermatol.2011.98.

    Article  PubMed  Google Scholar 

  31. Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 2011;81(4). https://doi.org/10.1016/j.ijrobp.2011.01.023.

  32. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–92. https://doi.org/10.1016/j.jaad.2014.10.014.

    Article  PubMed  Google Scholar 

  33. Schaff EM, Rosenberg SA, Olson SJ, Howard SP, Bradley KA. Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides. Radiat Oncol. 2018;13(1). https://doi.org/10.1186/s13014-018-1013-2.

  34. Oka T, Miyagaki T. Novel and future therapeutic drugs for advanced mycosis fungoides and Sézary syndrome. Front Med. 2019;6:116. https://doi.org/10.3389/fmed.2019.00116.

    Article  Google Scholar 

  35. Rupoli S, Barulli S, Guiducci B, Offidani M, Mozzicafreddo G, Simonacci M, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T cell lymphoma multicenter study group. Haematologica. 1999;84(9):809–13.

    CAS  PubMed  Google Scholar 

  36. Jumbou O, Guyen JM, Tessier MH, Legoux B, Dréno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999;140(3):427–31. https://doi.org/10.1046/j.1365-2133.1999.02704.x.

    Article  CAS  PubMed  Google Scholar 

  37. Sugaya M, Tokura Y, Hamada T, Tsuboi R, Moroi Y, Nakahara T, et al. Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol. 2014;41(1):50–6. https://doi.org/10.1111/1346-8138.12341.

    Article  CAS  PubMed  Google Scholar 

  38. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–71. https://doi.org/10.1200/JCO.2001.19.9.2456.

    Article  CAS  PubMed  Google Scholar 

  39. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160(6):1299–307. https://doi.org/10.1111/j.1365-2133.2009.09037.x.

    Article  CAS  PubMed  Google Scholar 

  40. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581–93 Doi:10–1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-5-dst0039.

  41. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003;49(5):873–8. https://doi.org/10.1016/S0190-9622(03)01591-3.

    Article  PubMed  Google Scholar 

  42. Purnak S, Azar J, Mark LA. Etoposide as a single agent in the treatment of mycosis fungoides: a retrospective analysis. Dermatol Ther. 2018;31:31(2). https://doi.org/10.1111/dth.12586.

    Article  Google Scholar 

  43. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9. https://doi.org/10.1182/blood-2014-09-600924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. •• Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204. https://doi.org/10.1016/S1470-2045(18)30379-6 An open-label, international, phase III, randomized controlled trial of patients with relapsed or refractory MF/SS showed that mogamulizumab resulted in superior progression-free survival compared with vorinostat.

    Article  CAS  PubMed  Google Scholar 

  45. Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426–33. https://doi.org/10.1200/JCO.2016.67.8250.

    Article  PubMed  Google Scholar 

  46. Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–8. https://doi.org/10.1200/JCO.2014.60.3969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. •• Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–66. https://doi.org/10.1016/S0140-6736(17)31266-7 An international randomized phase III trial for MF patients with CD30 expression (at least 10% of tumor cells or lymphoid infiltrates) revealed that the proportion of patients achieving an OR lasting at least 4 months was 50% with brentuximab vedotin versus 10% with physician’s choice (methotrexate or bexarotene) in MF.

    Article  CAS  PubMed  Google Scholar 

  48. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100. https://doi.org/10.1182/blood-2013-12-542142.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003;101(11):4267–72. https://doi.org/10.1182/blood-2002-09-2802.

    Article  CAS  PubMed  Google Scholar 

  50. Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150(7):776–9. https://doi.org/10.1001/jamadermatol.2013.10099.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15. https://doi.org/10.1200/JCO.2006.10.2434.

    Article  CAS  PubMed  Google Scholar 

  52. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–7. https://doi.org/10.1200/JCO.2008.21.6150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–91. https://doi.org/10.1200/JCO.2010.28.9066.

    Article  CAS  PubMed  Google Scholar 

  54. O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. https://doi.org/10.1200/JCO.2010.29.9024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–22. https://doi.org/10.1182/blood-2011-11-390211.

    Article  CAS  PubMed  Google Scholar 

  56. Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017;23(14):3552–6. https://doi.org/10.1158/1078-0432.CCR-16-2064.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18(13):2603–6. https://doi.org/10.1200/JCO.2000.18.13.2603.

    Article  CAS  PubMed  Google Scholar 

  58. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51–8. https://doi.org/10.3816/CLM.2006.n.039.

    Article  CAS  PubMed  Google Scholar 

  59. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104(11):2437–41. https://doi.org/10.1002/cncr.21449.

    Article  CAS  PubMed  Google Scholar 

  60. Quereux G, Marques S, Nguyen JM, Bedane C, D’incan M, Dereure O, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol. 2008;144(6):727–33. https://doi.org/10.1001/archderm.144.6.727.

    Article  CAS  PubMed  Google Scholar 

  61. Di Lorenzo G, Di Trolio R, Delfino M, De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol. 2005;153(1):183–5. https://doi.org/10.1111/j.1365-2133.2005.06682.x.

    Article  CAS  PubMed  Google Scholar 

  62. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol. 2001;114(3):624–31. https://doi.org/10.1046/j.1365-2141.2001.02919.x.

    Article  CAS  PubMed  Google Scholar 

  63. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009;15(8):982–90. https://doi.org/10.1016/j.bbmt.2009.04.017.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28(29):4492–9. https://doi.org/10.1200/JCO.2010.29.3241.

    Article  PubMed  Google Scholar 

  65. Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–8. https://doi.org/10.1200/JCO.2014.57.5597.

    Article  PubMed  Google Scholar 

  66. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49(11):1360–5. https://doi.org/10.1038/bmt.2014.161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5. https://doi.org/10.1093/annonc/mdv473.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol. 2020;38:266–71. https://doi.org/10.1002/hon.2719.

    Article  CAS  PubMed  Google Scholar 

  69. Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, et al. Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - lymphoma study group. J Dermatol. 2013;40(1):2–14. https://doi.org/10.1111/j.1346-8138.2012.01639.x.

    Article  PubMed  Google Scholar 

  70. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014–30. https://doi.org/10.1016/j.ejca.2006.01.025.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Hiroaki Kamijo MD, PhD

  2. Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

    Tomomitsu Miyagaki MD, PhD

Authors
  1. Hiroaki Kamijo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomomitsu Miyagaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hiroaki Kamijo MD, PhD or Tomomitsu Miyagaki MD, PhD.

Ethics declarations

Conflict of Interest

Hiroaki Kamijo declares that he has no conflict of interest.

Tomomitsu Miyagaki declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamijo, H., Miyagaki, T. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Curr. Treat. Options in Oncol. 22, 10 (2021). https://doi.org/10.1007/s11864-020-00809-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00809-w

Keywords

Search

Navigation